Cardiovascular Outcomes of Cholinesterase Inhibitors in Individuals with Dementia: A Meta-Analysis and Systematic Review

Acetylcholinesterase inhibitors are associated with weight loss in older people with dementia: a systematic review and meta-analysis

(2016) Pinar Soysal et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Exclusion of patients with concomitant chronic conditions in ongoing randomised controlled trials targeting 10 common chronic conditions and registered at ClinicalTrials.gov: a systematic review of registration details

(2016) Céline Buffel du Vaure et al.   BMJ Open

Association between acetylcholinesterase inhibitors and risk of stroke in patients with dementia

(2016) Yi-Ting Lin et al.   Scientific Reports

The influence of cholinesterase inhibitor therapy for dementia on risk of cardiac pacemaker insertion: a retrospective, population-based, health administrative databases study in Ontario, Canada

(2015) Allen R Huang et al.   BMC Neurology

Novel strategies and underlying protective mechanisms of modulation of vagal activity in cardiovascular diseases

(2015) Xi He et al.   BRITISH JOURNAL OF PHARMACOLOGY

Asymptomatic Bradycardia Due to Rivastigmine in an Elderly Adult with Lewy Body Dementia

(2015) Pinar Soysal et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Impact of acetylcholinesterase inhibitors on the occurrence of acute coronary syndrome in patients with dementia

(2015) Ping-Hsun Wu et al.   Scientific Reports

Adverse Effects of Cholinesterase Inhibitors in Dementia, According to the Pharmacovigilance Databases of the United-States and Canada

(2015) Thibault B. Ali et al.   PLoS One

Which Rivastigmine Formula is Better for Heart in Elderly Patients With Alzheimer’s Disease

(2014) Ahmet Turan Isik et al.   American Journal of Alzheimers Disease and Other Dementias

Cardiovascular pharmacodynamics of donepezil hydrochloride on the PR and QT intervals in patients with dementia

(2014) Hirofumi Igeta et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

High-Dose Cholinergic Therapy With Rivastigmine Patch Does Not Prolong QTc Time in Patients With Alzheimer’s Disease

(2014) Matthias W. Riepe   JOURNAL OF CLINICAL PSYCHIATRY

Antioxidant Activity of Galantamine and Some of its Derivatives

(2013) D. Tsvetkova et al.   CURRENT MEDICINAL CHEMISTRY

The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer's disease

(2013) Peter Nordström et al.   EUROPEAN HEART JOURNAL

Which Cholinesterase Inhibitor is the Safest for the Heart in Elderly Patients With Alzheimer’s Disease?

(2012) Ahmet Turan Isik et al.   American Journal of Alzheimers Disease and Other Dementias

Use of Rivastigmine or Galantamine and Risk of Adverse Cardiac Events: A Database Study from the Netherlands

(2012) Edeltraut Kröger et al.   American Journal Geriatric Pharmacotherapy

Efficacy and Safety of Donepezil 23 mg versus Donepezil 10 mg for Moderate-to-Severe Alzheimer’s Disease: A Subgroup Analysis in Patients Already Taking or Not Taking Concomitant Memantine

(2012) Rachelle S. Doody et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

Cardiac Safety of Donepezil in Elderly Patients with Alzheimer Disease

(2012) Ahmet Turan Isik et al.   INTERNAL MEDICINE

Influences of Donepezil on Cardiovascular System—Possible Therapeutic Benefits for Heart Failure—DOnepezil Cardiac TEst Registry (DOCTER) Study

(2012) Toru Kubo et al.   JOURNAL OF CARDIOVASCULAR PHARMACOLOGY

Evaluation of the effects of galantamine on cardiac function in elderly patients with Alzheimer's disease

(2011) Ahmet Turan Isik et al.   American Journal Geriatric Pharmacotherapy

Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease

(2011) Martin Farlow et al.   BMC Neurology

Galantamine (Reminyl) once daily outcome and satisfaction survey (RODOS) in mild to moderate Alzheimer's disease: A study in a real life population

(2011) Katrien Van Puyvelde et al.   Geriatrics & Gerontology International

The Effect of Donepezil Treatment on Cardiovascular Mortality

(2010) K Sato et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study

(2010) Martin R. Farlow et al.   CLINICAL THERAPEUTICS

GALANTAMINE DOES NOT CAUSE AGGRAVATED ORTHOSTATIC HYPOTENSION IN PEOPLE WITH ALZHEIMER'S DISEASE

(2010) Arenda H. E. A. van Beek et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Late onset Alzheimer’s disease in older people

(2010) Ahmet Turan Isik   Clinical Interventions in Aging

Switching from Donepezil Tablets to Rivastigmine Transdermal Patch in Alzheimer's Disease

(2009) Carl H. Sadowsky et al.   American Journal of Alzheimers Disease and Other Dementias

Syncope and Its Consequences in Patients With Dementia Receiving Cholinesterase Inhibitors

(2009) Sudeep S. Gill et al.   ARCHIVES OF INTERNAL MEDICINE

Safety and Tolerability of Donepezil at Doses up to 20 mg/day

(2009) Rachelle S Doody et al.   DRUGS & AGING

Cholinesterase Inhibitors and Incidence of Bradycardia in Patients with Dementia in the Veterans Affairs New England Healthcare System

(2009) Rohini K. Hernandez et al.   JOURNAL OF THE AMERICAN GERIATRICS SOCIETY

Cholinesterase Inhibitors and Hospitalization for Bradycardia: A Population-Based Study

(2009) Laura Y. Park-Wyllie et al.   PLOS MEDICINE

The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration

(2009) Alessandro Liberati et al.   PLOS MEDICINE

Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study

(2008) C. Ballard et al.   CURRENT MEDICAL RESEARCH AND OPINION